Results 171 to 180 of about 2,195 (197)
Some of the next articles are maybe not open access.
Dermatomal rash after Shingrix vaccination: cause or coincidence?
Baylor University Medical Center Proceedings, 2022Dermatological reactions have been reported following Shingrix vaccine administration in previous published cases, but dermatomal rash after Shingrix vaccination has not been reported in the United States. This case describes a 73-year-old immunocompetent woman with a dermatomal rash after Shingrix recombinant vaccine administration.
Nitish Mittal, Nikita Dhir, Neha Mittal
openaire +2 more sources
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine
Annals of Pharmacotherapy, 2018Objectives: To review the immunogenicity, efficacy, and safety of the herpes zoster subunit vaccine (HZ/su) for use in adult patients for the prevention of shingles. Data Sources: A literature search through PubMed was conducted (June 2008 to October 2017) using the terms shingles vaccine and varicella zoster virus.
James, Stephanie +3 more
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster
Nursing for Women's Health, 2018Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime.
Jacqueline R. Sly, Allyssa L. Harris
openaire +2 more sources
[Zoster disease after Shingrix vaccination].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2021Shingrix is a recombinant adjuvant subunit vaccine. The vaccine is approved in Germany for prevention of zoster manifestation and postherpetic neuralgia in adults aged ≥60 years. In the case of bullous skin lesions after vaccination with Shingrix a zoster disease should be considered.
D, Kohn, T, Wetzig
openaire +1 more source
Shingrix for Herpes Zoster: A Review
Skin therapy letter, 2020Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along
Radhika A, Shah +5 more
openaire +1 more source
Shingrix : A New Vaccine for Shingles
2023Therapeutics Letter 114 looks at Shingrix, a new vaccine for shingles. Conclusions: Compared to placebo the Shingrix vaccine reduced the incidence of herpes zoster by 3.26 % (NNV = 31) over 3.5 years in all age groups and reduced the incidence of post-herpetic neuralgia by 0.28% (NNV ≈ 350).
openaire +1 more source
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Drugs & Aging, 2018Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years.
openaire +2 more sources
Shingrix: A New Herpes Zoster Vaccine.
P & T : a peer-reviewed journal for formulary managementShingrix, a new vaccine for herpes zoster.
Fraidy, Maltz, Brooke, Fidler
openaire +1 more source